Open Interest and Volume Dynamics
On 23 Jan 2026, Alkem Laboratories recorded an open interest (OI) of 19,609 contracts in its derivatives, marking a substantial increase of 3,742 contracts or 23.58% compared to the previous OI of 15,867. This sharp rise in OI is accompanied by a volume of 15,697 contracts, indicating strong participation and fresh positions being established in the market.
The futures segment alone accounted for a value of approximately ₹50,857 lakhs, while the options segment’s notional value soared to an impressive ₹6,604.72 crores, culminating in a total derivatives value of ₹51,026.54 lakhs. Such elevated figures underscore the growing interest in Alkem’s derivatives, suggesting that traders are positioning themselves for potential price movements in the near term.
Price Performance and Technical Context
Alkem Laboratories’ underlying stock closed at ₹5,774, just 2.74% shy of its 52-week high of ₹5,933.5. The stock has outperformed its Pharmaceuticals & Biotechnology sector by 1.19% on the day, while the broader Sensex and sector indices declined by 0.75% and 0.86% respectively. This relative strength is further supported by the stock’s two-day consecutive gains, delivering a cumulative return of 2.1% over this period.
Technically, Alkem is trading above all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – signalling a sustained uptrend. The rising delivery volume of 1.91 lakh shares on 22 Jan, which surged 57.17% above the five-day average, indicates increased investor conviction and participation in the stock’s rally.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
Market Positioning and Directional Bets
The surge in open interest alongside rising volumes suggests that market participants are actively building positions, likely anticipating further upside in Alkem Laboratories’ stock. The increase in OI by 23.58% is a strong indicator of fresh capital inflows rather than mere position rollovers or squaring off.
Given the stock’s proximity to its 52-week high and its outperformance relative to the sector and benchmark indices, traders appear to be adopting a bullish stance. The elevated futures and options values imply that both hedgers and speculators are engaged, with options activity hinting at increased interest in calls, which typically reflects expectations of upward price movement.
However, the stock’s Mojo Score of 62.0 and a Mojo Grade of Hold, downgraded from Buy on 1 Dec 2025, suggest a cautious approach. While the technicals and volume patterns are positive, the fundamental assessment advises investors to monitor developments closely before committing to aggressive positions.
Liquidity and Tradeability
Alkem Laboratories boasts a market capitalisation of ₹69,042.81 crores, categorising it as a mid-cap stock within the Pharmaceuticals & Biotechnology sector. The stock’s liquidity is robust, with a 2% threshold of the five-day average traded value supporting trade sizes up to ₹1.71 crores comfortably. This liquidity profile facilitates smooth execution of large trades without significant price impact, attracting institutional and retail investors alike.
The delivery volume spike further confirms strong investor interest, which is crucial for sustaining momentum and validating the recent open interest expansion.
Alkem Laboratories Ltd or something better? Our SwitchER feature analyzes this mid-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Outlook and Investor Considerations
While the derivatives data points to a bullish tilt, investors should weigh this against the recent downgrade in Mojo Grade from Buy to Hold. This adjustment reflects a more tempered view on the stock’s near-term fundamentals despite its technical strength and market positioning.
Investors are advised to monitor key triggers such as quarterly earnings, regulatory developments, and sectoral trends that could influence Alkem’s trajectory. The pharmaceutical sector remains sensitive to policy changes and competitive pressures, which could impact valuations and investor sentiment.
In summary, the sharp rise in open interest and volume in Alkem Laboratories’ derivatives market signals increased market engagement and a probable directional bias towards the upside. However, the Hold rating and mid-cap status counsel a balanced approach, favouring selective participation with risk management in place.
Summary of Key Metrics:
- Open Interest: 19,609 contracts (up 23.58%)
- Volume: 15,697 contracts
- Futures Value: ₹50,857 lakhs
- Options Value: ₹6,604.72 crores
- Underlying Price: ₹5,774 (2.74% below 52-week high)
- Mojo Score: 62.0 (Hold, downgraded from Buy on 1 Dec 2025)
- Market Cap: ₹69,042.81 crores (Mid Cap)
- Delivery Volume: 1.91 lakh shares (up 57.17% vs 5-day average)
Overall, Alkem Laboratories remains a stock to watch closely as market participants position for potential gains, supported by strong technicals and active derivatives trading. Investors should remain vigilant to evolving market conditions and fundamental cues to optimise their exposure.
Unlock special upgrade rates for a limited period. Start Saving Now →
